BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data

-3.95%

NRX Pharmaceuticals, Inc.

NRXP

1.70

-3.95%

Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:

NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE) FOLLOWING TYPE C FDA MEETING
NRX PHARMACEUTICALS INC - CO TO SEEK BROADER INDICATION FOR NRX-100 FOR DEPRESSION
NRX PHARMACEUTICALS: WILL USE CLINICAL TRIAL DATA IN HAND WITH PROPOSED REAL WORLD DATA FROM OSMIND TO APPLY FOR NRX-100 APPROVAL
NRX PHARMACEUTICALS INC - FDA ADVISES NO ADDITIONAL NONCLINICAL DATA NEEDED FOR NRX APPLICATION
NRX PHARMACEUTICALS INC - BELIEVES PATH FOR NRX-100 APPROVAL BASED ON EXISTING DATA

Source text: ID:nGNX6ZvC4Z

Further company coverage: NRXP.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.